KRAS targeted therapies face subtype efficacy challenges

Recent clinical developments and research are reshaping the landscape of KRAS-targeted therapies for cancer. In colorectal cancer, studies are investigating how tumors adapt to KRAS G12C inhibitors. While combining KRAS G12C inhibitors like sotorasib with anti-EGFR antibodies such as panitumumab has shown significant improvements in progression-free survival, researchers are now using spatial transcriptomics to understand the mechanisms behind treatment resistance.

Simultaneously, data from Revolution Medicines regarding its pan-RAS inhibitor, Rasonque (daraxonrasib), has revealed varying efficacy across different KRAS mutation subtypes. While the drug showed strong results in the RASolute 302 study for pancreatic cancer, FDA review documents indicate an objective response rate (ORR) of only 24% for the KRAS G12D subtype, compared to 50% for G12V.

This differentiation has sparked market interest in highly selective KRAS G12D inhibitors. Companies are increasingly focusing on this specific mutation, which accounts for 35% to 40% of KRAS mutations in real-world settings. Notable industry activity includes Revolution Medicines' ongoing development of zoldonrasib and Merck’s significant investment in a preclinical KRAS G12D inhibitor from Sipure Medicine.